Urothelial Barrier Function and Interstitial Cystitis

Information

  • Research Project
  • 6711567
  • ApplicationId
    6711567
  • Core Project Number
    R21DK066075
  • Full Project Number
    1R21DK066075-01
  • Serial Number
    66075
  • FOA Number
    RFA-DK-03-10
  • Sub Project Id
  • Project Start Date
    9/30/2003 - 21 years ago
  • Project End Date
    8/31/2005 - 19 years ago
  • Program Officer Name
    MULLINS, CHRISTOPHER V.
  • Budget Start Date
    9/30/2003 - 21 years ago
  • Budget End Date
    8/31/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/22/2003 - 21 years ago
Organizations

Urothelial Barrier Function and Interstitial Cystitis

DESCRIPTION (provided by applicant): The aetiology of interstitial cystitis (IC) and other chronic inflammatory uropathies is not understood. We propose to develop a model system in which the urothelium will be studied in isolation from modulatory histio-environmental factors in order to address whether there is an inherent dysfunction in the urothelium, in at least a subset of painful bladder diseases. Our experimental strategy will be to remove modulatory histio-environmental factors by establishing urothelial cells from IC and control patients in a defined in vitro cell culture system. The model system will permit direct comparison of the phenotypic, functional and immunological characteristics of urothelial cells from IC and normal urothelium. We propose to use this system to test a novel hypothesis, namely that the disease is perpetuated by a failure of the urothelium to provide adequate barrier function against the ingress of urine, leading to tissue damage and consequent inflammation. We will further determine if this can arise due to an inherent defect of the urothelium itself, or due to abnormal responses to inflammatory cytokines produced as a consequence of transient infection or trauma. To these ends, we will study the urothelial cell cultures for their ability to a) Undergo differentiation, b) Form a functional barrier urothelium and c) Show a normal response to archetypal pro- and anti-inflammatory cytokines. The work will be important in establishing whether urothelial cells from patients with IC are inherently abnormal, or whether the aetiopathology of IC is secondary to other factors. The power of this approach lies in its capability of providing evidence of disease subsets and its potential to reveal targets for therapy.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R21
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    108000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    849
  • Ed Inst. Type
  • Funding ICs
    NIDDK:108000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF YORK
  • Organization Department
  • Organization DUNS
    228074605
  • Organization City
    YORK
  • Organization State
  • Organization Country
    UNITED KINGDOM
  • Organization Zip Code
    YO10 5DD
  • Organization District
    UNITED KINGDOM